Salix Pharmaceuticals has in-licensed the US rights for two products Pepcid® and Diuril® from Merck & Co. for US$61 M. In another licensing agreement, Debiopharm Group granted Salix the right to sell, market and distribute the orphan drug Sanvar® IR.